Cardiovascular Complications of Novel Anti-Cancer Immunotherapy: Old Problems from New Agents?

Woo-Baek Chung MD, Jong-Chan Youn MD, PhD, and Ho-Joong Youn MD, PhD

Division of Cardiology, Department of Internal Medicine, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea

ABSTRACT

Many novel anti-cancer therapies have dramatically improved outcomes of various cancer patients. However, it also poses a risk for cardiovascular complications as well. For the novel anti-cancer agent with which physicians do not have enough clinical experiences to determine the characteristics of cardiovascular complications, it is important to assess risk factors for cardiotoxicity before starting anti-cancer therapy. High-risk patient should be consulted to cardiologist before initiating anti-cancer therapy and pre-emptive cardiac function monitoring plan might be prepared in advance. The biomarkers, electrocardiography and echocardiography are useful tools for the detection of subclinical cardiotoxicity during anti-cancer therapy. This review article tried to suggest the cardiac function monitoring strategies for newly encountered potential cardiotoxic anti-cancer agents and to summarize the cardiovascular complications of novel anti-cancer immunotherapies including immune checkpoint inhibitor (ICI) and chimeric antigen receptor (CAR) T-cell therapy. ICIs can cause fatal myocarditis, which usually occurs early after initiation, and prompt treatment with high-dose corticosteroid is necessary. CAR T-cell therapy can cause cytokine release syndrome, which may result in circulatory collapse. Supportive treatment as well as tocilizumab, an anti-interleukin-6 receptor antibody are cornerstones of treatment.

Keywords: Anti-cancer therapy; Cardiovascular toxicity; Cancer immunotherapy; Immune checkpoint inhibitor; Chimeric antigen receptor T cell therapy

INTRODUCTION

According to the national statistics of Korea, two leading causes of death in 2018 were cancer and cardiovascular disease. There are many evidences that both conditions share common risk factors and each affects the prognosis of the other. Most cardiologists are aware of that some anti-cancer agents can cause acute and chronic cardiovascular toxic effect. There were many efforts to understand the pathophysiology of cardiotoxicity of anti-cancer agents and to detect early changes of cardiac function during chemotherapeutic periods. However, the innovation of anti-cancer therapy challenges cardiologists to establish new cardiac function monitoring strategy for novel anti-cancer agents, such...
CV Complications of Novel Anti-Cancer Immunotherapy

(NRF-2018R1C1B6005448). The funders played no role in study design, data collection, data analysis, decision to publish, or preparation of the manuscript.

Conflict of Interest
The authors have no financial conflicts of interest.

Author Contributions
Conceptualization: Chung WB, Youn JC, Youn HJ; Data curation: Chung WB, Youn JC, Youn HJ; Formal analysis: Chung WB, Youn JC; Funding acquisition: Youn JC; Investigation: Youn JC, Youn HJ; Resources: Youn JC, Youn HJ; Software: Youn JC; Supervision: Youn JC, Youn HJ; Validation: Chung WB, Youn JC; Writing - original draft: Chung WB, Youn JC, Youn HJ; Writing - review & editing: Chung WB, Youn JC, Youn HJ.

as immune check point inhibitors. It is important for cardiologists to be familiar with current strategies for cardiac function monitoring on updated recommendations of not only cardiology,4-6) but also oncology societies,18-20) to deal with cardiotoxicity of unfamiliar anti-cancer agents. This review tried to suggest the cardiac function monitoring strategies for newly encountered potential cardiotoxic anti-cancer agents and to summarize the cardiovascular complications of novel anti-cancer immunotherapies including immune checkpoint inhibitor (ICI) and chimeric antigen receptor (CAR) T-cell therapy.

CARDIAC FUNCTION MONITORING STRATEGY FOR NEWLY ENCOUNTERED POSSIBLE CARDIOTOXIC ANTI-CANCER AGENTS

Screening before initiation of anti-cancer therapy
For the novel anti-cancer agent that physician does not have enough clinical experiences with to determine the characteristics of cardiovascular complications, it is important to assess risk factors for cardiotoxicity before starting anti-cancer therapy. Common risk factors are listed in Table 1.

Patient with high-risk for the development of cardiotoxicity should be consulted to cardiologist before initiating novel anti-cancer therapy and pre-emptive cardiac function monitoring plan should be prepared in advance. Sharing information of novel anti-cancer agents and treatment schedule can help not only cardiologist but also oncologist to manage unexpected cardiotoxic complication of new agents.

Monitoring strategy for cardiovascular complication of novel anti-cancer agent
The biomarkers and electrocardiogram (ECG) are useful tools for the detection of subclinical cardiotoxicity during cancer treatment. Elevation of troponins (troponin-I and -T) and brain natriuretic peptide (BNP)/N-terminal proBNP (NT-proBNP) are very sensitive surrogate marker for detection of early myocardial damage.21)22) Troponin-I (Tn-I) level elevates within

### Table 1. Risk factors for development of cardiotoxicity before anti-cancer therapy

| Risk factors                                                                 |
|------------------------------------------------------------------------------|
| Age (<10 years old or ≥75 years old)                                        |
| Concomitant cardiovascular risk factors                                     |
| Hypertension (including development during the period of anti-cancer therapy)|
| Diabetes                                                                      |
| Dyslipidemia                                                                  |
| Smoking (current or ex-smoker)                                               |
| Obesity                                                                       |
| Sedentary lifestyle                                                          |
| Concomitant cardiovascular disease                                           |
| Coronary artery disease                                                      |
| Baseline LV dysfunction (LVEF <53%)                                          |
| Baseline elevation of biomarkers over normal limit (troponin-I, troponin-T, BNP, NT-proBNP) |
| Baseline ECG abnormality (ST segment abnormalities, QT prolongation, etc.)   |
| History of cardiotoxic anti-cancer therapy                                   |
| Previous anthracyline treatment                                              |
| Previous trastuzumab treatment                                               |
| Previous mediastinal or chest radiotherapy                                   |

BNP = brain natriuretic peptide; ECG = electrocardiogram; LV = left ventricular; LVEF = left ventricular ejection fraction; NT-proBNP = N terminal pro-BNP.

https://e-kcj.org

https://doi.org/10.4070/kcj.2020.0158
72 hours after anthracycline based chemotherapy and some patients maintain high Tn-I level after 1 month. NT-proBNP level also rose in breast cancer patients with asymptomatic reduction of left ventricular ejection fraction (LVEF). NT-proBNP was measured every 3 weeks in this study and LVEF was measured baseline and at the end of 4 cycle of doxorubicin based chemotherapy. Most recommendations did not suggest timing of biomarker evaluation, but it may need to be measured within 2–3 weeks after each cycle of novel anti-cancer therapy for the early detection of subclinical cardiotoxicity.

Tyrosine kinase inhibitors are well known for QT prolongation and concomitant atrial fibrillation in cancer patients is at high risk for thromboembolic events. It is important to assess ECG repeatedly to detect changes from baseline ECG and concomitant arrhythmia before and during the treatment. There are no definite recommended intervals for ECG assessment, but cardiologist and oncologist may determine the schedule according to novel anti-cancer agent treatment protocol before initiating therapy.

It is now routine practice that assessment of baseline LVEF before initiating anti-cancer therapy by imaging modalities. European society of cardiology recommended to use echocardiography, nuclear cardiac imaging (multigated radionuclide angiography; MUGA) and cardiac magnetic resonance (CMR) imaging to detect cardiotoxicity. Recently oncology society recommends echocardiography as a first-line imaging modality because it can provide additional information such as global longitudinal strain. MUGA is no longer recommended for the assessment of LVEF because non-irradiating imaging modality is usually more preferred. Because routine use of repetitive CMR imaging is not yet clinically feasible in most centers, echocardiography is the most appropriate modality for cardiac function monitoring during cancer treatment. Normal cut-off value of LVEF is 50% in recommendations of some societies and 53% in other societies. Normal cut-off values of LVEF is 53% by echocardiography or 50% by MUGA. Proposed cardiotoxicity monitoring strategy for novel anti-cancer therapy is demonstrated in Figure 1.

There is no precise recommendation for the surveillance of cardiac function after cancer therapy, especially in new agents which has little information about cardiotoxicity. Echocardiographic evaluation of at 3-6 months interval may be reasonable for cardiac

**Proposed cardiotoxicity monitoring strategy for novel anti-cancer therapy**

- **Assessment of risk factors**  
  - Prepare plan for anti-cancer therapy  
  - Prepare monitoring plan for cardiotoxicity

- **Echocardiography at 3-6 months interval for 1 year**

**Diagnosis**

- Detection of asymptomatic cardiotoxicity  
  - Assessment of biomarkers after each cycle  
  - Assessment of ECG after each cycle  
  - Echocardiography at 3 months interval

**Therapeutic periods with anti-cancer therapy**

- Initiation of planned therapy

**Post surveillance**

- Termination of planned therapy

**Figure 1.** Proposed cardiotoxicity monitoring strategy for novel anti-cancer therapy.
function monitoring after completion of novel anti-cancer therapy despite a few evidence. Post treatment surveillance can be also discussed and planned before initiating cancer treatment between cardiologists and oncologists.

**CARDIOVASCULAR COMPLICATIONS OF CANCER IMMUNOTHERAPIES**

Cancer immunotherapy including ICI and CAR T-cell therapy has dramatically improved outcomes of various cancer patients. ICI is a novel anti-cancer therapy that amplifies T cell mediated immune responses against cancer cells. They increase antitumor immunity by blocking intrinsic down regulators of immunity, such as cytotoxic T-lymphocyte antigen 4 (CTLA-4) and programmed cell death 1 (PD-1) or its ligand, programmed cell death ligand 1 (PD-L1). Several ICIs have increased overall survival for patients with various cancers and are approved by the US Food and Drug Administration (FDA) (Table 2).

CAR T-cells are T lymphocytes that have been genetically modified to express T-cell receptors (TCRs) that can recognize tumor-specific antigens. In CAR T-cell immunotherapy, the patient’s own T cells are extracted, genetically engineered to target tumor-associated antigens, expanded, and infused back into the patient's body where they continue to multiply, recognize, and destroy cancer cells. The US FDA has approved 2 agents that express CD19 on the surface. These agents are currently approved and used for refractory or relapsed acute lymphocytic leukemia and diffuse large B-cell lymphoma. However, preliminary results from several phase I clinical trials of CAR T cells targeting B-cell maturation antigen have shown highly encouraging results in relapsed/refractory multiple myeloma.

**Incidence**

In 2016, 2 cases of fatal fulminant myocarditis were reported following combination ICI therapy, both occurring after the first dose of therapy. Further interrogation of immunotherapy trial data revealed 18 cases (0.09%) of myocarditis among 20,594 subjects in the pharmacovigilance database. The incidence of myocarditis was higher in patients receiving a combination of nivolumab and ipilimumab (0.27%) than in those receiving nivolumab alone (0.06%). Of concern, 50% of ICI-associated myocarditis cases were fatal. A cohort study of patients from a multicenter registry reported a prevalence of 1.14%, which increased to as high as 2.4% for combination therapy with anti-PD-1/anti-CTLA-4. Among 101 cases of ICI associated myocarditis from World Health Organization's VigiBase, 64% occurred after the first or second dose, and 76% occurred within the first 6 weeks of treatment.

**Table 2. US Food and Drug Administration-approved immune check point inhibitors and indications**

| Drug      | Target      | Indications                                                                 |
|-----------|-------------|-----------------------------------------------------------------------------|
| Ipilimumab| CTLA-4      | Melanoma                                                                     |
| Nivolumab | PD-1        | Melanoma, NSCLC, RCC, HCC, HL, SCC of the head and neck, urothelial carcinoma, colorectal carcinoma with high microsatellite instability or mismatch repair deficiency |
| Pembrolizumab | PD-1    | Melanoma, NSCLC, HL, SCC of the head and neck, urothelial carcinoma, gastric tumors, solid tumors with high microsatellite instability or mismatch repair deficiency |
| Atezolizumab | PD-L1    | NSCLC, urothelial carcinoma                                                  |
| Avelumab  | PD-L1        | Merkel cell carcinoma, urothelial carcinoma                                  |
| Durvalumab | PD-L1        | Urothelial carcinoma                                                         |
| Cemiplimab | PD-1        | Metastatic cutaneous SCC or locally advanced SCC                             |

CTLA-4 = cytotoxic T-lymphocyte antigen 4; HCC = hepatocellular carcinoma; HL = Hodgkin lymphoma; NSCLC = non-small cell lung cancer; PD-1 = programmed cell death 1; PD-L1 = programmed cell death ligand 1; RCC = renal cell carcinoma; SCC = squamous cell carcinoma.
cases of ICI-associated myocarditis from 8 centers revealed that 81% occurred within the first 4 cycles of ICI therapy (median 34 days from start of therapy). Recently, operational definition of cancer therapy associated myocarditis was proposed to facilitate case ascertainment and to report and therefore to enhance the understanding of the incidence, outcomes, and risk factors. ICI-associated cardiotoxic effects can extend beyond myocarditis. Heart failure with left ventricular dysfunction but without the evidence of myocarditis on biopsy, pericardial disease and temporal arteritis can also occur. Arrhythmias and cardiac conduction disease were common cardiotoxic effects including atrial fibrillation (30%), ventricular tachyarrhythmia (27%) and conduction abnormalities (17%).

Cytokine release syndrome (CRS) is the most known toxicity of CAR T cells and consists of a constellation of signs and symptoms caused by inflammatory cytokines released by the activated CAR T cells and other immune cells. Although CRS is reported to occur frequently (58–93%, Table 3), the toxic effects mediated by the cytokine release are mostly mild. However, 20–50% of patients with CRS develop life-threatening complications such as vascular leak syndrome with circulatory collapse and multiorgan failure. Symptom onset can occur within minutes to hours or days after infusion begins, coinciding with maximal T-cell expansion. Median time to development of CRS after CAR T-cell infusion is 2.2 days. The highest risk is in the first 2 weeks after infusion but theoretically it could occur as long as CAR T cells persist in the circulation, which could be years. In the pivotal randomized clinical trials, myocardial infarction was not observed, cardiac arrest was reported in 4 patients with death occurring in 1 patient, and heart failure in 2 patients following CAR T-cell therapy.

Mechanisms
Although the exact pathophysiology of ICI associated cardiotoxicity is not well understood, suggested mechanisms include a shared antigen or homologous antigen between the tumor and myocardium or certain TCRs targeting dissimilar antigens. These are analogous to proposed mechanisms of viral-mediated myocarditis in which the heart is targeted by a process of molecular mimicry. As in viral myocarditis, ICI associated myocarditis has been described to have T-cell infiltration of the myocardium. Preclinical studies also revealed that CTLA-4, PD-1, and PD-L1 have also important roles in cardiac immune regulation, with abrogation of this pathway resulting in autoimmune myocarditis and cardiac failure. Fatal autoimmune myocarditis mediated by CD8 T cells was noted in CTLA-4 knockout mice. Deletion of PD-1 in mice showed development of spontaneous myocarditis and dilated cardiomyopathy.

Cytokine release is an expected effect (on-target) caused by immune activation by CAR T cells and is mostly mild, however, some patients develop life-threatening complications caused by systemic circulatory collapse. Underlying mechanism of severe cardiac dysfunction during CRS is unclear, but resembles cardiomyopathy associated with sepsis and stress. Among a wide variety of cytokines, interleukin-6 (IL-6) is considered to be a key mediator of the systemic adverse effects. Rarely, off-target cross-reactivity against titin may also occur, which may lead to cardiogenic shock, and 2 deaths have been attributed to this cause.

| Trial   | Type of cancer                        | Type of CAR T cell      | CRS (%) |
|---------|---------------------------------------|-------------------------|---------|
| ZUMA-1  | Relapsed/refractory large B-cell lymphoma | Axicabtagene            | 94/101 (93.1) |
| ELIANA  | Relapsed/refractory B-cell lymphoblastic leukemia | Tisagenlecleucel       | 58/75 (77.3) |
| JULIET  | Relapsed/refractory diffuse large B-cell lymphoma | Tisagenlecleucel       | 64/111 (57.7) |

CAR = chimeric antigen receptor; CRS = cytokine release syndrome.
Diagnosis

Because ICI associated myocarditis is a diagnosis of exclusion, it is important to rule out other more common cardiac conditions including acute coronary syndrome or stress induced cardiomyopathy. The initial guidelines for the management of immune related adverse events separated myocarditis into 4 grades of severity (grade 1–grade 4), with grade 1 being the mildest and grade 4 being the most severe by way of a life-threatening clinical presentation. The guidelines recommended that any grade of severity required further workup, which entailed cardiac biomarkers, ECG, chest x-ray, echocardiogram, and consideration of CMR and invasive testing, such as coronary angiography and endomyocardial biopsy (EMB). The clinical syndrome associated with myocarditis is broad and can encompass a spectrum of symptoms including palpitations, chest pain and dyspnea. Biomarkers for myocardial necrosis is important for the diagnosis of ICI associated myocarditis. Registry data show that troponin was the most sensitive test, with increased troponin level noted in 94% of patients with myocarditis. However, an increased troponin level is not specific for myocarditis, and a normal troponin level, especially in cases that appear late after initiation of ICIs, does not exclude ICI associated myocarditis. Troponin level has also been shown to have prognostic value in patients with ICI myocarditis, with a higher troponin level associated with worse outcomes. CMR is the gold standard noninvasive test for the diagnosis of myocarditis because of its excellent spatial resolution and additive ability to provide tissue characterization. Increased capillary permeability associated with myocarditis leads to increased myocardial water content and cellular necrosis, which can be detected by CMR on T1- and T2-weighted images, late gadolinium enhancement and extracellular volume fraction. CMR has sensitivity of 76% and specificity of 96% for diagnosing myocarditis of other causes. The Lake Louise Criteria, for the CMR diagnosis of myocarditis, have been developed and validated. EMB is considered as the gold standard for the diagnosis of myocarditis. Although it is highly specific for diagnosis, the myocardial involvement with ICI-associated myocarditis is usually patchy, which makes EMB less sensitive. Recently, operational definition of cancer therapy-associated myocarditis was proposed to categorize the event in terms of the level of certainty (definite, probable, and possible) with which myocarditis can be defined (Table 4).

The hallmarks of CRS are fever and tachycardia that may be associated with hypotension and hypoxia. It is a systemic inflammatory response that can affect multiple organs, ranging in severity from mild to severe, with life-threatening conditions including cardiac dysfunction, adult respiratory distress syndrome, neurologic toxicity, coagulopathy, and liver and renal

| Table 4. Proposed definition of myocarditis in cancer therapy |
|---------------------------------------------------------------|
| **Definition of myocarditis in cancer therapy**               |
| **Definite myocarditis**                                     |
| Pathology or                                                  |
| Diagnostic CMR imaging + syndrome + (biomarker or ECG) or    |
| New WMA on echocardiography + syndrome + biomarker + ECG + negative angiography |
| **Probable myocarditis**                                     |
| Diagnostic CMR imaging (no syndrome, ECG, biomarker) or      |
| Suggestive CMR imaging with either syndrome, ECG or biomarker or |
| WMA on echocardiography and syndrome (with either biomarker or ECG) or |
| Syndrome with PET evidence and no alternative diagnosis     |
| **Possible myocarditis**                                     |
| Suggestive CMR imaging with no syndrome, ECG or biomarker or |
| WMA on echocardiography with syndrome or ECG only or         |
| Elevated biomarker with syndrome or ECG and no alternative diagnosis |

CMR = cardiac magnetic resonance; ECG = electrocardiography; PET = positron emission tomography; WMA = wall motion abnormality.
failure.\textsuperscript{20} However, sepsis, tumor lysis syndrome, pulmonary embolism, primary cardiac event and other systemic illness should be excluded for the diagnosis of CRS. The grading of CRS has varied among different centers using commercially approved and investigational T-cell therapy, making toxicity and management comparisons between studies difficult.\textsuperscript{29}

Recently, multidisciplinary expert group reported a consensus CRS grading scale using fever, hypotension, and hypoxia as principal determinants and grading of severity based on the need for vasopressor support and supplemental oxygen requirement (Table 5).\textsuperscript{54}

### Table 5. American Society for Transplantation and Cellular Therapy cytokine release syndrome consensus grading

| CRS parameter | Grade 1 | Grade 2 | Grade 3 | Grade 4 |
|---------------|---------|---------|---------|---------|
| Fever         | ≥38°C   | ≥38°C   | ≥38°C   | ≥38°C   |
| Hypotension   | None    | Not requiring vasopressors | Requiring a vasopressor with or without vasopressin | Requiring multiple vasopressors (excluding vasopressin) |
| Hypoxia       | None    | Requiring low-flow nasal cannula or blow-by | Requiring high-flow nasal cannula, facemask, nonrebreather mask, or Venturi mask | Requiring positive pressure (e.g., CPAP, BiPAP, intubation and mechanical ventilation) |

Fever is defined as temperature ≥38°C not attributable to any other cause. In patients who have CRS then receive antipyretic or anti-cytokine therapy such as tocilizumab or steroids, fever is no longer required to grade subsequent CRS severity. In this case, CRS grading is driven by hypotension and/or hypoxia. CRS grade is determined by the more severe event: hypotension or hypoxia not attributable to any other cause. For example, a patient with temperature of 39.5°C, hypotension requiring 1 vasopressor, and hypoxia requiring low-flow nasal cannula is classified as grade 3 CRS. Low-flow nasal cannula is defined as oxygen delivered at ≤6 L/min. Low flow also includes blow-by oxygen delivery, sometimes used in pediatrics. High-flow nasal cannula is defined as oxygen delivered at >6 L/min. BiPAP = bilevel positive airway pressure; CPAP = continuous positive airway pressure; CRS = cytokine release syndrome.

### Management and long-term surveillance

The management of ICI associated myocarditis is largely based on early clinical experience.\textsuperscript{27} Cessation of ICI therapy and immunosuppression are the cornerstones of treatment. High-dose corticosteroids (methylprednisolone 1,000 mg/day for first 3 day followed by oral prednisone 1 mg/kg) are usually the first line of therapy in the acute phase. Antithymocyte globulin and intravenous immunoglobulin can be considered for unstable patients. Concomitant standard heart failure management should also be initiated, especially if the LVEF is reduced. While the optimal length of treatment with immunosuppressive agents is not clear, it is reasonable to continue until resolution of symptoms and normalization of LVEF, biomarker and conduction abnormality.\textsuperscript{27} Surveillance for cardiotoxicity in patients receiving ICI can be helpful for prompt recognition and risk stratification, particularly for high-risk patients such as those with preexisting autoimmune disease, diabetes, or cardiovascular comorbidities.\textsuperscript{27} However, currently, there are no guidelines regarding screening and surveillance of ICI-related cardiotoxicity in asymptomatic patients.

The management of CAR T-cell therapy related CRS is also based on clinical experience without clear guidelines. Supportive care includes inotropes and ventilation supports for hypotension and hypoxia. Patients should be transferred to an intensive care unit if vasopressor or mechanical ventilation is required. Tocilizumab, a monoclonal anti-IL-6 receptor antibody is approved by the FDA as a first-line agent to be used for the management of CRS-related toxicity.\textsuperscript{50} Tocilizumab 8 mg/kg infused over 1 hour, maximum 800 mg per dose, repeat every 8 hours as needed for patients with grade 2–4 CRS. Some concerns exist that tocilizumab may lessen the efficacy of the CAR T cells as it is unclear to what extent the cytokine-mediated immune response is required for the antitumor response.\textsuperscript{20,26} Thus, there has been some hesitation toward its utilization in early CRS. There is no universal consensus regarding the timing of tocilizumab initiation (with respect to the severity of CRS) and practices are likely to vary among different institutions.\textsuperscript{29} Corticosteroids are also effective in the treatment of CRS but are generally considered as second-line therapy.\textsuperscript{27}
CONCLUSION

Many novel anti-cancer therapies including cancer immunotherapies have dramatically improved outcomes of various cancer patients. However, considering the increasing burden of cardiotoxicity of novel anti-cancer therapies, additional effort needs to be directed toward formulating specific evidence-based recommendations for the monitoring of novel anti-cancer therapy and the pre-emptive prevention of cardiotoxicity.

REFERENCES

1. Pareek N, Cevallos J, Moliner P, et al. Activity and outcomes of a cardio-oncology service in the United Kingdom—a five-year experience. *Eur J Heart Fail* 2018;20:1721-31.
   [PUBMED] [CROSSREF]

2. Masoudkabir F, Sarrazadegan N, Gotay C, et al. Cardiovascular disease and cancer: evidence for shared disease pathways and pharmacologic prevention. *Atherosclerosis* 2017;263:343-51.
   [PUBMED] [CROSSREF]

3. Meijers WC, de Boer RA. Common risk factors for heart failure and cancer. *Cardiovasc Res* 2019;115:844-53.
   [PUBMED] [CROSSREF]

4. Plana JC, Galderisi M, Barac A, et al. Expert consensus for multimodality imaging evaluation of adult patients during and after cancer therapy: a report from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. *Eur Heart J Cardiovasc Imaging* 2014;15:1063-93.
   [PUBMED] [CROSSREF]

5. Zamorano JL, Lancellotti P, Rodriguez Muñoz D, et al. 2016 ESC position paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for practice guidelines: the task force for cancer treatments and cardiovascular toxicity of the European Society of Cardiology (ESC). *Eur Heart J* 2016;37:2768-801.
   [PUBMED] [CROSSREF]

6. Kim H, Chung WB, Cho KI, et al. Diagnosis, treatment, and prevention of cardiovascular toxicity related to anti-cancer treatment in clinical practice: an opinion paper from the working group on cardio-oncology of the Korean Society of Echocardiography. *J Cardiovasc Ultrasound* 2018;26:1-25.
   [PUBMED] [CROSSREF]

7. Youn JC, Han S, Ryu KH. Temporal trends of hospitalized patients with heart failure in Korea. *Korean Circ J* 2017;47:16-24.
   [PUBMED] [CROSSREF]

8. Choi HM, Park MS, Youn JC. Update on heart failure management and future directions. *Korean J Intern Med* 2019;34:11-43.
   [PUBMED] [CROSSREF]

9. Kim DY, Youn JC, Park MS, et al. Cardiovascular outcome of breast cancer patients with concomitant radiotherapy and chemotherapy: a 10-year multicenter cohort study. *J Cardiol* 2019;74:175-81.
   [PUBMED] [CROSSREF]

10. Kim KJ, Cho HJ, Kim MS, et al. Focused update of 2016 Korean Society of Heart failure guidelines for the management of chronic heart failure. *Int J Heart Fail* 2019;1:4-24.
    [CROSSREF]

11. Lee JH, Kim MS, Yoo BS, et al. KSHF guidelines for the management of acute heart failure: part II. Treatment of acute heart failure. *Korean Circ J* 2019;49:22-45.
    [PUBMED] [CROSSREF]

12. Stewart Coats AJ. Common co-morbidities in heart failure – diabetes, functional mitral regurgitation and sleep apnoea. *Int J Heart Fail* 2019;1:25-41.
    [CROSSREF]

13. Lee HY, Oh BH. Paradigm shifts of heart failure therapy: do we need another paradigm? *Int J Heart Fail*. 2020 [Epub ahead of print].
    [CROSSREF]

14. Uhm JS, Chung WB, Yoon JS, Oh YS, Youn HJ. Effects of adriamycin and candesartan on the collagen and elastin of the aorta in rats. *Clin Hypertens* 2014;20:8.
    [PUBMED] [CROSSREF]
15. Chung WB, Youn HJ. Pathophysiology and preventive strategies of anthracycline-induced cardiotoxicity. *Korean J Intern Med* 2016;31:625-33.

16. Chung WB, Yi JE, Jin JY, et al. Early cardiac function monitoring for detection of subclinical doxorubicin cardiotoxicity in young adult patients with breast cancer. *J Breast Cancer* 2013;16:178-83.

17. Gripp EA, Oliveira GE, Feijo LA, Garcia MI, Xavier SS, Sousa AS. Global longitudinal strain accuracy for cardiotoxicity prediction in a cohort of breast cancer patients during anthracycline and/or trastuzumab treatment. *Ang Bras Cardiol* 2018;110:140-50.

18. Armenian SH, Llacchetti C, Barac A, et al. Prevention and monitoring of cardiac dysfunction in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline. *J Clin Oncol* 2017;35:893-911.

19. Virizuela JA, García AM, de Las Peñas R, et al. SEOM clinical guidelines on cardiovascular toxicity (2018). *Clin Transl Oncol* 2019;21:94-105.

20. Curigliano G, Lenihan D, Fradley M, et al. Management of cardiac disease in cancer patients throughout oncological treatment: ESMO consensus recommendations. *Ann Oncol* 2020;31:171-90.

21. Zardavas D, Suter TM, Van Veldhuisen DJ, et al. Role of troponins I and T and N-terminal prohormone of brain natriuretic peptide in monitoring cardiac safety of patients with early-stage human epidermal growth factor receptor 2-positive breast cancer receiving trastuzumab: a Herceptin Adjuvant study cardiac marker substudy. *J Clin Oncol* 2017;35:878-84.

22. Michel L, Mincu RJ, Mahabadi AA, et al. Troponins and brain natriuretic peptides for the prediction of cardiotoxicity in cancer patients: a meta-analysis. *Eur J Heart Fail* 2020;22:350-61.

23. Cardinale D, Iacopo F, Cipolla CM. Cardiotoxicity of anthracyclines. *Front Cardiovasc Med* 2020;7:26.

24. Michel L, Rassaf T, Totzeck M. Biomarkers for the detection of apparent and subclinical cancer therapy-related cardiotoxicity. *J Thorac Dis* 2018;10:S4282-95.

25. Kittiwarawut A, Vorasettakarnkij Y, Tanasanvimon S, Manasnayakorn S, Sriuranpong V. Serum NT-proBNP in the early detection of doxorubicin-induced cardiac dysfunction. *Asia Pac J Clin Oncol* 2013;9:155-61.

26. Negishi T, Miyazaki S, Negishi K. Echocardiography and cardio-oncology. *Heart Lung Circ* 2019;28:1331-8.

27. Ganatra S, Parikh R, Neilan TG. Cardiotoxicity of immune therapy. *Cardiol Clin* 2019;37:385-97.

28. Postow MA, Sidlow R, Hellmann MD. Immune-related adverse events associated with immune checkpoint blockade. *N Engl J Med* 2018;378:158-68.

29. Ganatra S, Carver JR, Hayek SS, et al. Chimeric antigen receptor T-cell therapy for cancer and heart: JACC council perspectives. *J Am Coll Cardiol* 2019;74:3153-63.

30. Johnson DB, Balko JM, Compton ML, et al. Fulminant myocarditis with combination immune checkpoint blockade. *N Engl J Med* 2016;375:1749-55.

31. Mahmood SS, Fradley MG, Cohen JV, et al. Myocarditis in patients treated with immune checkpoint inhibitors. *J Am Coll Cardiol* 2018;71:1795-64.

32. Moslehi JJ, Salem JE, Sosman JA, Lebrun-Vignes B, Johnson DB. Increased reporting of fatal immune checkpoint inhibitor-associated myocarditis. *Lancet* 2018;391:933.

33. Lyon AR, Yousaf N, Battisti NM, Moslehi J, Larkin J. Immune checkpoint inhibitors and cardiovascular toxicity. *Lancet Oncol* 2018;19:e447-58.
34. Bonaca MP, Olenchock BA, Salem JE, et al. Myocarditis in the setting of cancer therapeutics: proposed case definitions for emerging clinical syndromes in cardio-oncology. *Circulation* 2019;140:80-91.

35. Escudier M, Cautela J, Malissen N, et al. Clinical features, management, and outcomes of immune checkpoint inhibitor-related cardiotoxicity. *Circulation* 2017;136:2085-7.

36. Salem JE, Manouchehr A, Moey M, et al. Cardiovascular toxicities associated with immune checkpoint inhibitors: an observational, retrospective, pharmacovigilance study. *Lancet Oncol* 2018;19:1579-89.

37. Obetfeld AE, Frey NV, Mansfield K, et al. Cytokine release syndrome associated with chimeric-antigen receptor T-cell therapy: clinicopathological insights. *Blood* 2017;130:2569-72.

38. Neelapu SS, Lockle FL, Bartlett NL, et al. Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma. *N Engl J Med* 2017;377:2531-44.

39. Maude SL, Laetsch TW, Buechner J, et al. Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia. *N Engl J Med* 2018;378:439-48.

40. Schuster SJ, Bishop MR, Tam CS, et al. Tisagenlecleucel in adult relapsed or refractory diffuse large B-cell lymphoma. *N Engl J Med* 2019;380:45-56.

41. Palaskas N, Lopez-Mattei J, Durand JB, Iliescu C, Deswal A. Immune checkpoint inhibitor myocarditis: pathophysiological characteristics, diagnosis, and treatment. *J Am Heart Assoc* 2020;9:e013757.

42. Love VA, Grabie N, Duramad P, Stavrakis G, Sharpe A, Lichtman A. CTLA-4 ablation and interleukin-12 driven differentiation synergistically augment cardiac pathogenicity of cytotoxic T lymphocytes. *Circ Res* 2007;101:248-57.

43. Okazaki T, Tanaka Y, Nishio R, et al. Autoantibodies against cardiac troponin I are responsible for dilated cardiomyopathy in PD-1-deficient mice. *Nat Med* 2003;9:1477-83.

44. Nishimura H, Okazaki T, Tanaka Y, et al. Autoimmune dilated cardiomyopathy in PD-1 receptor-deficient mice. *Science* 2001;291:319-22.

45. Lichtman AH. The heart of the matter: protection of the myocardium from T cells. *J Autoimmun* 2013;45:90-6.

46. Tarrio ML, Grabie N, Bu DX, Sharpe AH, Lichtman AH. PD-1 protects against inflammation and myocyte damage in T cell-mediated myocarditis. *J Immunol* 2012;188:4876-84.

47. Pathan N, Hemingway CA, Alizadeh AA, et al. Role of interleukin 6 in myocardial dysfunction of meningococcal septic shock. *Lancet* 2004;363:203-9.

48. Linette GP, Stadtmauer EA, Maus MV, et al. Cardiovascular toxicity and titin cross-reactivity of affinity-enhanced T cells in myeloma and melanoma. *Blood* 2013;122:863-71.

49. Brahmer JR, Lacchetti C, Schneider BJ, et al. Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: American Society of Clinical Oncology clinical practice guideline. *J Clin Oncol* 2018;36:1714-68.

50. Friedlich MG, Sechtem U, Schulz-Menger J, et al. Cardiovascular magnetic resonance in myocarditis: a JACC white paper. *J Am Coll Cardiol* 2009;53:1475-87.

51. Ferreira VM, Schulz-Menger J, Holmvang G, et al. Cardiovascular magnetic resonance in nonischemic myocardial inflammation: expert recommendations. *J Am Coll Cardiol* 2018;72:3158-76.

52. Mahrholdt H, Goedecke C, Wagner A, et al. Cardiovascular magnetic resonance assessment of human myocarditis: a comparison to histology and molecular pathology. *Circulation* 2004;109:1250-8.
53. Abdel-Aty H, Boyé P, Zagrosek A, et al. Diagnostic performance of cardiovascular magnetic resonance in patients with suspected acute myocarditis: comparison of different approaches. *J Am Coll Cardiol* 2005;45:1815-22. [PUBMED](https://doi.org/10.1016/j.jacc.2005.03.009) [CROSSREF](https://doi.org/10.1016/j.jacc.2005.03.009)

54. Lee DW, Santomasso BD, Locke FL, et al. ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells. *Biol Blood Marrow Transplant* 2019;25:625-38. [PUBMED](https://doi.org/10.1016/j.bbmt.2018.09.011) [CROSSREF](https://doi.org/10.1016/j.bbmt.2018.09.011)

55. Le RQ, Li L, Yuan W, et al. FDA approval summary: tocilizumab for treatment of chimeric antigen receptor T cell-induced severe or life-threatening cytokine release syndrome. *Oncologist* 2018;23:943-7. [PUBMED](https://doi.org/10.1634/theoncolo.2018-0299) [CROSSREF](https://doi.org/10.1634/theoncolo.2018-0299)

56. Davila ML, Riviere I, Wang X, et al. Efficacy and toxicity management of 19–28z CAR T cell therapy in B cell acute lymphoblastic leukemia. *Sci Transl Med* 2014;6:224ra25. [PUBMED](https://doi.org/10.1126/scitranslmed.3009030) [CROSSREF](https://doi.org/10.1126/scitranslmed.3009030)